Biopharmaceutical company focused on the development of targeted immunotherapies with a VLP B-cell vaccines platform and ongoing preclinical development programs based on the platform
Location: Switzerland, Zurich, Schlieren
Total raised: $26.28M
Investors 2
| Date | Name | Website |
| - | Aisling Ca... | aislingcap... |
| - | Life Scien... | lspvc.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 18.11.2013 | - | $26.28M | - |
Mentions in press and media 6
| Date | Title | Description |
| 03.12.2015 | Kuros and Cytos merge | |
| 12.08.2015 | Checkmate nets $20M to develop drug that boosts checkpoint inhibitor efficacy | Checkmate Pharmaceuticals operates on the idea that checkpoint inhibitor therapies would be much more effective if they were combined with an agent that could stimulate a person’s immune response. So, on top of the new financing, it’s also ... |
| 14.04.2014 | Cytos on the point of getting out | |
| 18.11.2013 | Cytos raises CHF24million | |
| 23.03.2012 | Cytos to raise up to CHF 37 million | |
| - | Checkmate nets $20M to develop drug that boosts checkpoint inhibitor efficacy | The name of the company’s pretty pithy: Checkmate Pharmaceuticals, so-called because its drug in development serves as a “mate” to checkpoint inhibitors, enhancing their efficacy. The Cambridge company just launched with a $20 million Serie... |